Modified Radical Prostatectomy for Prostate Cancer Patients With Enlarged Prostate and Severe Lower Urinary Tract Symptoms: a Single-center, Retrospective Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Sun Yat-sen University
- Enrollment
- 30
- Locations
- 1
- Primary Endpoint
- Biochemical Recurrence-free Survival
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The goal of this retrospective, observational study is to preliminarily learn about the safety and efficacy of two-step radical prostatectomy in the treatment of low- to intermediate-risk prostate cancer patients with enlarged prostate and severe benign prostatic hyperplasia. The main questions it aims to answer are: 1. Whether two-step prostatectomy is safe enough to decrease the surgical difficulty of these patients? 2. Whether the oncologic control is promising?
Investigators
Yonghong Li
Professor
Sun Yat-sen University
Eligibility Criteria
Inclusion Criteria
- •Diagnosed as prostate cancer pathologically by prostate biopsy Evaluated as localized prostate cancer by imaging studies Prostate volume\>70mL evaluated by transrectal ultrasonography or multi-parametric magnetic resonance imaging Gleason score≤ 4+3=7 Preoperative PSA\<20ng/mL Estimated survival\> 10 years； Informed consent is obtained from the patient
Exclusion Criteria
- •The patient has received other therapy including radical radiotherapy, transurethral resection of the prostate, cryoablation, HIFU, etc.
- •Any contraindication of surgery or anaesthesia
Outcomes
Primary Outcomes
Biochemical Recurrence-free Survival
Time Frame: 5 years
Number of participants who are free of biochemical relapse after a specified duration of time. Biochemical recurrence is measured by PSA levels. Biochemical recurrence was defined as a measurable serum PSA concentration 0.2 ng/ml or greater.
Secondary Outcomes
- Continence ContinenceContinence Continence Continence Continence Continence Continence Continence Continence(2 weeks, 1 months, 3 months, 6 months, 12 months after surgery)
- Lower urinary tract symptoms(1 months, 3 months, 6 months, 12 months after surgery)
- Estimated blood loss(Intraoperative)
- Erectile function(6 months, 12 months and 24 months after surgery)
- Positive surgical margin rate(Through study completion, an average of 5 year)
- Surgical time(Intraoperative)
- Hospital stay(From date of surgery until the date of discharge, an average of 7 days)
- Complication(Through study completion, an average of 5 year)